NanoViricides drafts Phase II trial protocol for NV-387 measles treatment
NNVC•NNVC•NNVC•NNVC•NanoViricides moved toward a Phase II trial of NV-387 to treat measles, with a draft protocol now in circulation.
Clinical results have not been presented; the program is still being prepared for an FDA IND process.
NV-387 is positioned as a potential measles treatment in a market with no approved drug option for infected patients.
Strategic upside includes FDA Rare Pediatric Disease Drug status, which could support a Priority Review Voucher upon a successful marketing application.
A recent Priority Review Voucher sale cited in the announcement was valued at USD 195 million, highlighting potential non-commercialization cash value.
